Do analysts recommend ASMB or MOR?

Assembly Biosciences presently has a consensus target price of $45.60, suggesting a potential upside of 38.73%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor SUPN or ASMB?

In the previous week, Assembly Biosciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Assembly Biosciences' score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Assembly Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASMB or BHC?

In the previous week, Assembly Biosciences had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.04 beat Assembly Biosciences' score of 0.59 indicating that Bausch Health Cos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLYS or ASMB?

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 6 mentions for Assembly Biosciences. Mineralys Therapeutics' average media sentiment score of 1.29 beat Assembly Biosciences' score of 0.59 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Assembly Biosciences (ASMB) Competitors

$32.87 -2.41 (-6.83%)

Closing price 04:00 PM Eastern

Extended Trading

$33.60 +0.73 (+2.22%)

As of 05:55 PM Eastern

Compare

ASMB vs. MOR, ATAI, SUPN, BHC, and MLYS

Should you buy Assembly Biosciences stock or one of its competitors? Assembly Biosciences's main competitors and comparable companies include MorphoSys (MOR), Atai Beckley (ATAI), Supernus Pharmaceuticals (SUPN), Bausch Health Cos (BHC), and Mineralys Therapeutics (MLYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Assembly Biosciences compare to MorphoSys?

Assembly Biosciences (NASDAQ:ASMB) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Assembly Biosciences has a net margin of -0.06% compared to MorphoSys' net margin of -226.79%. Assembly Biosciences' return on equity of -0.02% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
MorphoSys	-226.79%	-694.31%	-22.55%

Assembly Biosciences has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	8.94	-$6.12M	$1.02	32.23
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Assembly Biosciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Assembly Biosciences presently has a consensus target price of $45.60, suggesting a potential upside of 38.73%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Assembly Biosciences had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Assembly Biosciences and 0 mentions for MorphoSys. Assembly Biosciences' average media sentiment score of 0.59 beat MorphoSys' score of 0.00 indicating that Assembly Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Assembly Biosciences	Positive
MorphoSys	Neutral

Summary

Assembly Biosciences beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Atai Beckley?

Assembly Biosciences (NASDAQ:ASMB) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Assembly Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Assembly Biosciences had 5 more articles in the media than Atai Beckley. MarketBeat recorded 6 mentions for Assembly Biosciences and 1 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.82 beat Assembly Biosciences' score of 0.59 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Assembly Biosciences	Positive
Atai Beckley	Positive

Assembly Biosciences has a net margin of -0.06% compared to Atai Beckley's net margin of -14,938.36%. Assembly Biosciences' return on equity of -0.02% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Assembly Biosciences currently has a consensus target price of $45.60, indicating a potential upside of 38.73%. Atai Beckley has a consensus target price of $10.56, indicating a potential upside of 44.80%. Given Atai Beckley's higher possible upside, analysts plainly believe Atai Beckley is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Assembly Biosciences has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	8.94	-$6.12M	$1.02	32.23
Atai Beckley	$4.47M	604.56	-$660.05M	-$2.18	N/A

Summary

Assembly Biosciences beats Atai Beckley on 10 of the 16 factors compared between the two stocks.

How does Assembly Biosciences compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Assembly Biosciences (NASDAQ:ASMB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 49.35%. Assembly Biosciences has a consensus price target of $45.60, indicating a potential upside of 38.73%. Given Supernus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Assembly Biosciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Assembly Biosciences' score of 0.59 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Assembly Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

19.9% of Assembly Biosciences shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Assembly Biosciences has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.40	-$38.55M	-$1.92	N/A
Assembly Biosciences	$74.85M	8.94	-$6.12M	$1.02	32.23

Assembly Biosciences has a net margin of -0.06% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

Summary

Assembly Biosciences beats Supernus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Bausch Health Cos?

Assembly Biosciences (NASDAQ:ASMB) and Bausch Health Cos (NYSE:BHC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Assembly Biosciences has a net margin of -0.06% compared to Bausch Health Cos' net margin of -10.12%. Assembly Biosciences' return on equity of -0.02% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Bausch Health Cos	-10.12%	-561.95%	6.31%

In the previous week, Assembly Biosciences had 2 more articles in the media than Bausch Health Cos. MarketBeat recorded 6 mentions for Assembly Biosciences and 4 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.04 beat Assembly Biosciences' score of 0.59 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch Health Cos	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Assembly Biosciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Bausch Health Cos has higher revenue and earnings than Assembly Biosciences. Bausch Health Cos is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$74.85M	8.94	-$6.12M	$1.02	32.23
Bausch Health Cos	$10.27B	0.22	$157M	-$2.96	N/A

Assembly Biosciences currently has a consensus price target of $45.60, suggesting a potential upside of 38.73%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 30.19%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Summary

Assembly Biosciences beats Bausch Health Cos on 11 of the 17 factors compared between the two stocks.

How does Assembly Biosciences compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Assembly Biosciences (NASDAQ:ASMB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Assembly Biosciences. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 6 mentions for Assembly Biosciences. Mineralys Therapeutics' average media sentiment score of 1.29 beat Assembly Biosciences' score of 0.59 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Assembly Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Mineralys Therapeutics has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Assembly Biosciences' return on equity of -0.02% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-57.97%	-54.15%
Assembly Biosciences	-0.06%	-0.02%	-0.02%

Mineralys Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Assembly Biosciences has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A
Assembly Biosciences	$74.85M	8.94	-$6.12M	$1.02	32.23

Mineralys Therapeutics presently has a consensus target price of $48.80, suggesting a potential upside of 60.00%. Assembly Biosciences has a consensus target price of $45.60, suggesting a potential upside of 38.73%. Given Mineralys Therapeutics' higher possible upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Assembly Biosciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Assembly Biosciences beats Mineralys Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Assembly Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASMB vs. The Competition

Export

Metric	Assembly Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$669.27M	$12.40B	$7.13B	$12.78B
Dividend Yield	N/A	2.59%	2.54%	9.15%
P/E Ratio	32.23	794.77	272.35	25.20
Price / Sales	8.94	756.54	696.03	107.06
Price / Cash	N/A	90.26	77.07	52.39
Price / Book	2.52	10.58	10.76	6.32
Net Income	-$6.12M	$2.82B	$3.48B	$357.86M
7 Day Performance	-10.48%	-2.26%	-1.38%	-0.39%
1 Month Performance	23.20%	2.41%	2.17%	-1.28%
1 Year Performance	41.99%	4.77%	20.74%	11.50%

Assembly Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASMB Assembly Biosciences	3.4536 of 5 stars	$32.87 -6.8%	$45.60 +38.7%	+51.3%	$669.27M	$74.85M	32.23	100	News Coverage High Trading Volume
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ATAI Atai Beckley	3.3085 of 5 stars	$7.34 -0.1%	$10.56 +43.8%	+61.1%	$2.72B	$4.47M	N/A	80	News Coverage Options Volume High Trading Volume
SUPN Supernus Pharmaceuticals	4.0481 of 5 stars	$43.97 -0.1%	$62.83 +42.9%	-7.4%	$2.56B	$718.95M	N/A	580
BHC Bausch Health Cos	2.7308 of 5 stars	$6.79 -0.6%	$8.00 +17.8%	-12.2%	$2.54B	$10.27B	N/A	20,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASMB) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Assembly Biosciences (ASMB) Competitors

ASMB vs. MOR, ATAI, SUPN, BHC, and MLYS

How does Assembly Biosciences compare to MorphoSys?

Summary

How does Assembly Biosciences compare to Atai Beckley?

Summary

How does Assembly Biosciences compare to Supernus Pharmaceuticals?

Summary

How does Assembly Biosciences compare to Bausch Health Cos?

Summary

How does Assembly Biosciences compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Assembly Biosciences (ASMB) Competitors

ASMB vs. MOR, ATAI, SUPN, BHC, and MLYS

How does Assembly Biosciences compare to MorphoSys?

Is ASMB or MOR more profitable?

Which has stronger earnings & valuation, ASMB or MOR?

Which has more volatility and risk, ASMB or MOR?

Do institutionals and insiders have more ownership in ASMB or MOR?

Do analysts recommend ASMB or MOR?

Does the media refer more to ASMB or MOR?

Summary

How does Assembly Biosciences compare to Atai Beckley?

Which has more volatility & risk, ASMB or ATAI?

Do insiders & institutionals have more ownership in ASMB or ATAI?

Does the media refer more to ASMB or ATAI?

Is ASMB or ATAI more profitable?

Do analysts prefer ASMB or ATAI?

Which has preferable valuation and earnings, ASMB or ATAI?

Summary

How does Assembly Biosciences compare to Supernus Pharmaceuticals?

Do analysts rate SUPN or ASMB?

Does the media favor SUPN or ASMB?

Do institutionals and insiders believe in SUPN or ASMB?

Which has more risk & volatility, SUPN or ASMB?

Which has stronger valuation and earnings, SUPN or ASMB?

Is SUPN or ASMB more profitable?

Summary

How does Assembly Biosciences compare to Bausch Health Cos?

Do insiders & institutionals hold more shares of ASMB or BHC?

Is ASMB or BHC more profitable?

Does the media prefer ASMB or BHC?

Which has more volatility and risk, ASMB or BHC?

Which has stronger earnings and valuation, ASMB or BHC?

Do analysts rate ASMB or BHC?

Summary

How does Assembly Biosciences compare to Mineralys Therapeutics?

Does the media refer more to MLYS or ASMB?

Is MLYS or ASMB more profitable?

Which has more risk and volatility, MLYS or ASMB?

Do insiders and institutionals hold more shares of MLYS or ASMB?

Which has better earnings and valuation, MLYS or ASMB?

Do analysts rate MLYS or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASMB vs. The Competition

Assembly Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools